Elevated SLC2A3 expression has been reported to correlate with adverse outcomes in tongue cancer, influences the epithelial-mesenchymal transition (EMT) in colorectal cancer, and is linked to detrimental TME changes, such as macrophage infiltration, in gastric and breast cancers [37-40]. This evidence concerns the gene SLC2A3 and colorectal cancer.